Until we get into a routine of consistently beating and raising our guidance, we’re going to be just ultra prudent in what we say because we don’t like being in situations where we’re not exceeding expectations. So that’s what’s behind what you’ve heard today regarding our guidance, and we’re committed to it. Han, do you want to add anything to that?
Han Kieftenbeld: No, I think that’s right. I think we said, look, the consumer trend as we’ve seen it in the market, and you can also see where we’ve been in the last few quarters as well as for the full year, will continue. Of course, there is an element of we’re keying off a larger base. If you look at brands like Biossance that obviously have a significant critical mass, but we expect strong well above market kind of leading growth but keying off a bigger base. So that certainly plays into it, too. And then as John said, on the ingredients side, we obviously have the three components, products, we’re pretty much basically sold out on capacity there. We have R&D collaboration and then the milestone aspect that will be in effect for both the DSM piece as well as the €“ as well as now the Givaudan deal coming into play.
Rachel Vatnsdal: Helpful. Maybe one last one on 2023 guidance if I could just squeeze it in here quickly. You talked a lot about potential sources of funding for the year, but can you just walk us through each of the puts and takes in terms of what are your outflows for the year? You have two of these, at least two of these short-term bridge loans. You also have paying out for Aprinnova cash burn. So net-net, how should we be thinking about these cash outflows and what’s your total cash burn guidance for the year? Thanks.
Han Kieftenbeld: Yes, sure. So first and foremost, if you look at €“ we obviously had, as I made known in my remarks, significant demand for cash as we were building out Barra Bonita, that’s going to be obviously a very different place, we’re going to be in €˜23. Hence, my guidance on CapEx being significantly reduced, that’s one. We had M&A activity in 2022. We made known that we do not plan any M&A activity in €˜23. So that’s a number that we expect to go to zero from that vantage point. And then, of course, the whole Fit-to-Win agenda plays into it. We’ve confirmed again that it’s $150 million. I gave a few examples of things we’re doing to underpin progress in a number of areas particularly as well as the supply chain, the parcel shipping example I gave, expect $15 million to $20 million savings over the next 3 years of that agreement.
So there is a lot of things. Those are just samples or examples, so to speak, but there is a lot that’s going on that will bring down our cost of goods sold as well as operating expense for that matter, so both on the operating side as well as the investing side. And then on the outflow, you mentioned the €“ of course, the upfront consideration from Givaudan coming in. We do indeed need to pay the Aprinnova shareholding that we took. And other than that, we €“ from a debt reduction perspective, we have one payment to make, but the rest is all €˜24 or later.
Operator: The next question comes from Korinne Wolfmeyer of Piper Sandler. Please go ahead.
Korinne Wolfmeyer: Hey, good afternoon. And thanks for taking the question. So I’d like to first dive a little bit further into some of these brand divestitures that you noted. I think in the past, you’ve talked about longer-term targeting maybe like 10 to 12 brands in the portfolio. Is that still like a longer-term target you have in play or are you kind of readjusting your longer-term viewpoint now?
